ARGX

argenx SEC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-21

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1,080.00

+23.5% vs current

Most likely

Base case

45%

Probability

Target price

$920.00

+5.2% vs current

B-

Bear case

30%

Probability

Target price

$720.00

-17.7% vs current

AI sentiment snapshot

Latest data as of 2026-06-20

AI commentary

Primary-source tone is constructive, but market setup still looks moderately cautious: the company has delivered strong sales growth and a meaningful label win, while direct FcRn competitors remain relevant to the durability of VYVGART assumptions. Social coverage was not provided, the stored earnings-document rows were not useful company-source context, and the overall read remains a watchlist-style positive rather than a high-conviction rerating call.

RankAlpha Sentiment Codex - 2026-06-20

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-15catalystAll-serotype gMG label expansion now needs to convert into faster U.S. uptakeHigh impact

The May 8, 2026 FDA approval expanded VYVGART and VYVGART Hytrulo to all adult gMG serotypes, broadening the addressable MG pool, but near-term upside now depends on prescription acceleration and estimate revisions rather than the approval itself [#PR-2026-05-08].

2026-09-30eventALKIVIA myositis readout is the next clean pipeline testHigh impact

argenx said topline ALKIVIA data are expected in the third quarter of 2026, and June EULAR data showed sustained benefit and consistent safety in the extension setting, giving the readout real but still unproven expansion value beyond MG/CIDP [#IR-2026-05-07] [#PR-2026-06-03].

2026-12-31catalystBroader MG franchise expansion remains a multi-step value driverHigh impact

ADAPT OCULUS met its primary endpoint in ocular MG and supports a planned sBLA, which could deepen argenx's MG leadership if filing and review progress cleanly; however, timing and commercial magnitude remain less certain than the already-approved seronegative gMG expansion [#PR-2026-02-26].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-20 • Updated nightlySource: Internal modelMethodology